Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label bevacizumab + pemetrexed vs bevacizumab + pemetrexed + carboplatin in first-line advanced non-squamous NSCLC
2008-002035-33Phase 3Completed
- Sponsor
- Krankenhaus Martha-Maria Halle-Dölau
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Krankenhaus Martha-Maria Halle-Dölau. Primary endpoints: Objective Response and Progression-free survival. Started Oct 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-002035-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002035-33.